Biotech Values

[DewDiligence]

>Shire, Amicus, Actelion, Genzyme and Protalix.<

I guess you could say that’s a crowded market! Still, I wonder if HAE will be anywhere near as lucrative as Gaucher—the distinction being that HAE is a somewhat more manageable condition without a specialized therapy and hence payers may be less willing to reimburse for a hugely expensive drug.

#msg-28461053 is on-topic.